SCHEMBL30294752

SCHEMBL30294752

Cc1cc(F)ccc1Nc1cccc(F)c1C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FTO Q9C0B1 1/20 0.48
KMT2A Q03164 4/20 0.47
MEN1 O00255 3/20 0.47
MAPK1 P28482 1/20 0.47
FABP3 P05413 3/20 0.46
FABP4 P15090 3/20 0.46
MKNK2 Q9HBH9 1/20 0.43
MAPK13 O15264 1/20 0.43
MAPK12 P53778 1/20 0.43
MAPK11 Q15759 1/20 0.43
MAPK14 Q16539 1/20 0.43
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
GAA P10253 1/20 0.42
PKM P14618 1/20 0.42
GFER P55789 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
PLK1 P53350 1/20 0.41
CYP2C9 P11712 1/20 0.40
P2RY4 P51582 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22852801 1.00 FTO (0.48) FTOKMT2AMEN1MAPK1FABP3
SCHEMBL6036497 0.86 IDO1 (0.50) FTOKMT2AMEN1MAPK1FABP3
SCHEMBL22852851 0.86 PBRM1 (0.56) FTOKMT2AMEN1MAPK1FABP3
SCHEMBL30294311 0.86 PBRM1 (0.56) FTOKMT2AMEN1MAPK1FABP3
SCHEMBL30294497 0.84 MEN1 (0.43) KMT2AMEN1MAPK1FABP3FABP4
SCHEMBL22852844 0.84 TAS2R14 (0.49) KMT2AMEN1MAPK1FABP3FABP4
SCHEMBL22852780 0.84 MEN1 (0.43) KMT2AMEN1MAPK1FABP3FABP4
SCHEMBL30294602 0.84 TAS2R14 (0.49) KMT2AMEN1MAPK1FABP3FABP4
SCHEMBL22852776 0.80 KMT2A (0.50) FTOKMT2AMEN1MAPK1FABP3
SCHEMBL30294601 0.80 KMT2A (0.50) FTOKMT2AMEN1MAPK1FABP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230103791-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230103791-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS SCN8A, SCN1A, SCN1B FTO 4142/4885KMT2A 2375/4885MEN1 1826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.